Maturi, Raj

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 785

Yoga, Meditation and Mind-Body Health: Increased BDNF, Cortisol Awakening Response, and Altered Inflammatory Marker Expression after a 3-Month Yoga and Meditation Retreat

Cahn, B. R., Goodman, M. S., Peterson, C. T., Maturi, R., & Mills, P. J. (2017) · Frontiers in Human Neuroscience

Mindfulness and Compassion InterventionsStress Responses and Cortisol

Cited by 292

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration

Kunimoto, D., Yoon, Y. H., Wykoff, C. C., Chang, A., Khurana, R. N., Maturi, R. K., Agostini, H., Souied, E., Chow, D. R., Lotery, A. J., et al. (2020) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 91

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration

Callanan, D., Kunimoto, D., Maturi, R. K., Patel, S. S., Staurenghi, G., Wolf, S., Cheetham, J. K., Hohman, T. C., Kim, K., López, F. J., et al. (2018) · Journal of Ocular Pharmacology and Therapeutics

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 73

Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)

Altaweel, M. M., Daniel, E., Martin, D. F., Mittra, R. A., Grunwald, J. E., Lai, M. M., Melamud, A., Morse, L. S., Huang, J., Ferris, F. L., et al. (2015) · Ophthalmology

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 51